The Lord Lab is dedicated to translating scientific discoveries into better outcomes for patients through high-quality clinical research. The lab's mission is to advance innovative therapies by conducting clinical trials that evaluate new approaches to predicting, preventing and treating disease, while ensuring every participant receives exceptional care throughout their research journey.
The Lord Lab bridges laboratory discovery and patient care by conducting clinical research that advances promising scientific discoveries into real-world therapies. Through collaborations across Benaroya Research Institute and international research networks, the lab supports investigator-initiated and industry-sponsored studies focused on improving patient outcomes.
A major focus is co-leading the BRI Diabetes TrialNet Clinical Center. Through TrialNet, the lab conducts clinical trials that identify individuals at risk for T1D, evaluate therapies that delay or prevent disease onset and preserve insulin-producing beta cells. These studies have contributed to landmark advances in type 1 diabetes prevention and continue to shape the development of disease-modifying therapies.
The Lord Lab is equally committed to the participant experience. The lab believes exceptional clinical research begins with exceptional participant care, creating an environment where participants and their families feel informed, respected and supported throughout every stage of a study. By combining scientific rigor with compassionate, participant-centered care, the Lord Lab builds lasting partnerships that make transformative clinical research possible.
Sandra Lord, MD
Lab Members
Anna Barash, MSN, RN, CDCES
Archie Barash
Tyler Bartholome
Katie Bennett
Kassidy Benoscek
Erica Bourget
Natalie Clary
Arlene Colmenares
Isabella Franco Strand
Ren Green
Solomon Kassa
Rishab Kotak
David Lee
Drew MacFarlane
Ella McGuigan
Bao Ng, DNP, ARNP
Megan Olson
Kim Varner
Marlie Wells
Featured Publications
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.
J Clin Endocrinol Metab
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.
Nat Commun
OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals.
J Clin Endocrinol Metab
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Nat Commun
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.
J Endocr Soc
An Insider's Look Into Clinical Trials at BRI
Before medicines become widely available, they have to be rigorously tested — first in the lab, then in people through clinical trials.
The Current State of COVID-19: How Dangerous is Delta and Other Key Questions
At this point, we’ve lived through many phases of the pandemic: closing schools and sanitizing surfaces. Mask mandates and mRNA vaccines. Now, we’ve reached a new phase, with still more questions: How dangerous is the Delta variant?
Despite Possible Side Effects, Shoot for the COVID-19 Shot
Sore arm. Fever. Body aches. We’ve all heard about the possible side effects when it comes to getting the COVID-19 vaccine – but how serious are they? And what is happening in our bodies when we feel these reactions?
News
Recognizing BRI Researchers, Sheenam Verma and Sarah Kobernat, for Recent Fellowship Awards
Read More
Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason Franciscan Health, and GentiBio Highlight Long Standing Scientific Collaboration Advancing GNTI 122 Into the Clinic
Read More
